Core Insights - Shenzhen Yahui Long Biotechnology Co., Ltd. has received approval for its self-developed soluble CD146 detection kit (chemiluminescence method) from the Guangdong Provincial Drug Administration, marking a significant breakthrough in the detection of central nervous system diseases [1][2] - The company is the first globally to offer a soluble CD146 detection kit for cerebrospinal fluid, bringing its total number of domestic chemiluminescent reagent products to 173 [1] Group 1: Product Development and Innovation - The soluble CD146 detection kit demonstrates a notable increase in sCD146 concentration in cerebrospinal fluid among patients with multiple sclerosis (MS) and neuromyelitis optica, addressing the challenge of early and accurate diagnosis in these conditions [1][2] - Traditional laboratory testing methods have limitations, including complex procedures and long detection cycles, which the new chemiluminescence method overcomes by simplifying operations and enhancing sensitivity and specificity [1] Group 2: Clinical Implications and Market Position - The introduction of the soluble CD146 detection kit is expected to transition the field of central nervous system immune inflammatory demyelinating diseases from "diagnosable" to "precise and early diagnosis," laying a crucial foundation for disease intervention and prognosis improvement [2] - The collaboration with Academician Yan Xiyun, a prominent figure in nanobiology and tumor immunology, highlights the innovative nature of this project and strengthens China's international position in the diagnostic field for these diseases [2]

Core Insights - Aihuilong (688575.SH) has received approval from the Guangdong Provincial Drug Administration for its self-developed soluble CD146 detection kit (chemiluminescence method), marking a significant breakthrough in the detection of central nervous system diseases [1] - Aihuilong is the first company globally to possess a soluble CD146 detection kit for cerebrospinal fluid, bringing its total number of domestic chemiluminescent reagent products to 173 [1] Group 1: Clinical Significance - Research indicates that the concentration of soluble CD146 (sCD146) in cerebrospinal fluid is significantly elevated in patients with central nervous system autoimmune inflammatory demyelinating diseases, such as multiple sclerosis (MS) and neuromyelitis optica [2] - Traditional laboratory testing methods for these diseases have limitations, including complex procedures and long detection cycles, which Aihuilong's innovative chemiluminescence method aims to overcome by simplifying operations and enhancing sensitivity and specificity [2][3] - The sCD146 level in cerebrospinal fluid has shown a strong correlation with various inflammatory factors, making it a crucial auxiliary diagnostic marker for early and precise diagnosis of these diseases [2] Group 2: Technological Innovation - The soluble CD146 detection kit represents a groundbreaking technological achievement developed in collaboration with Professor Yan Xiyun, a renowned academician and expert in nanobiology [4] - This innovation not only transforms the diagnostic approach for central nervous system autoimmune inflammatory demyelinating diseases but also strengthens China's international leadership in this diagnostic field [4] - Aihuilong is conducting multi-center studies with Xuanwu Hospital to establish new diagnostic technologies and solutions based on sCD146, with plans to expand its application in various medical fields, including obstetrics, autoimmune diseases, cardiovascular diseases, and oncology [4]